378 related articles for article (PubMed ID: 15376304)
41. Hepatitis C.
Burra P
Semin Liver Dis; 2009 Feb; 29(1):53-65. PubMed ID: 19235659
[TBL] [Abstract][Full Text] [Related]
42. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation.
Chopra KB; Demetris AJ; Blakolmer K; Dvorchik I; Laskus T; Wang LF; Araya VR; Dodson F; Fung JJ; Rakela J; Vargas HE
Transplantation; 2003 Nov; 76(10):1487-91. PubMed ID: 14657691
[TBL] [Abstract][Full Text] [Related]
43. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months.
Orlando G; Manzia T; Baiocchi L; Sanchez-Fueyo A; Angelico M; Tisone G
Transpl Immunol; 2008 Nov; 20(1-2):43-7. PubMed ID: 18773958
[TBL] [Abstract][Full Text] [Related]
44. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome.
Watt KD; Lyden ER; Gulizia JM; McCashland TM
Liver Transpl; 2006 Jan; 12(1):134-9. PubMed ID: 16382465
[TBL] [Abstract][Full Text] [Related]
45. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
[TBL] [Abstract][Full Text] [Related]
46. Risk factors in patients with rapid recurrent hepatitis C virus-related cirrhosis within 1 year after liver transplantation.
Zimmermann T; Otto C; Hoppe-Lotichius M; Biesterfeld S; Lautem A; Knaak M; Zimmermann A; Barreiros AP; Heise M; Schattenberg JM; Sprinzl MF; Galle PR; Otto G; Schuchmann M
Transplant Proc; 2009; 41(6):2549-56. PubMed ID: 19715972
[TBL] [Abstract][Full Text] [Related]
47. Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression.
Alkhouri N; Hanouneh IA; Lopez R; Zein NN
Liver Transpl; 2010 Feb; 16(2):155-62. PubMed ID: 20104483
[TBL] [Abstract][Full Text] [Related]
48. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
[TBL] [Abstract][Full Text] [Related]
49. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.
Hissar SS; Kumar M; Tyagi P; Goyal A; Suneetha PV; Agarwal S; Rastogi A; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2009 Apr; 24(4):581-7. PubMed ID: 19032460
[TBL] [Abstract][Full Text] [Related]
50. Evolution of hepatitis C virus in liver allografts.
Demetris AJ
Liver Transpl; 2009 Nov; 15 Suppl 2():S35-41. PubMed ID: 19876940
[TBL] [Abstract][Full Text] [Related]
51. The natural history of hepatitis C cirrhosis after liver transplantation.
Firpi RJ; Clark V; Soldevila-Pico C; Morelli G; Cabrera R; Levy C; Machicao VI; Chaoru C; Nelson DR
Liver Transpl; 2009 Sep; 15(9):1063-71. PubMed ID: 19718647
[TBL] [Abstract][Full Text] [Related]
52. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis.
Berenguer M; Prieto M; Palau A; Rayón JM; Carrasco D; Juan FS; López-Labrador FX; Moreno R; Mir J; Berenguer J
Liver Transpl; 2003 Mar; 9(3):228-35. PubMed ID: 12619018
[TBL] [Abstract][Full Text] [Related]
53. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation.
Shiffman ML; Stravitz RT; Contos MJ; Mills AS; Sterling RK; Luketic VA; Sanyal AJ; Cotterell A; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Oct; 10(10):1248-55. PubMed ID: 15376308
[TBL] [Abstract][Full Text] [Related]
54. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.
Manousou P; Burroughs AK; Tsochatzis E; Isgro G; Hall A; Green A; Calvaruso V; Ma GL; Gale J; Burgess G; O'Beirne J; Patch D; Thorburn D; Leandro G; Dhillon AP
J Hepatol; 2013 May; 58(5):962-8. PubMed ID: 23262247
[TBL] [Abstract][Full Text] [Related]
55. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation.
Bosch W; Heckman MG; Pungpapong S; Diehl NN; Shalev JA; Hellinger WC
Transplantation; 2012 Apr; 93(7):723-8. PubMed ID: 22406819
[TBL] [Abstract][Full Text] [Related]
56. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients.
Takada Y; Haga H; Ito T; Nabeshima M; Ogawa K; Kasahara M; Oike F; Ueda M; Egawa H; Tanaka K
Transplantation; 2006 Feb; 81(3):350-4. PubMed ID: 16477219
[TBL] [Abstract][Full Text] [Related]
57. Contribution of obesity to hepatitis C-related fibrosis progression.
Ortiz V; Berenguer M; Rayón JM; Carrasco D; Berenguer J
Am J Gastroenterol; 2002 Sep; 97(9):2408-14. PubMed ID: 12358265
[TBL] [Abstract][Full Text] [Related]
58. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome.
Carmiel-Haggai M; Fiel MI; Gaddipati HC; Abittan C; Hossain S; Roayaie S; Schwartz ME; Gondolesi G; Emre S; Schiano TD
Liver Transpl; 2005 Dec; 11(12):1567-73. PubMed ID: 16315297
[TBL] [Abstract][Full Text] [Related]
59. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients.
Guo L; Orrego M; Rodriguez-Luna H; Balan V; Byrne T; Chopra K; Douglas DD; Harrison E; Moss A; Reddy KS; Williams JW; Rakela J; Mulligan D; Vargas HE
Liver Transpl; 2006 Apr; 12(4):560-5. PubMed ID: 16555313
[TBL] [Abstract][Full Text] [Related]
60. Progression of liver fibrosis among injection drug users with chronic hepatitis C.
Wilson LE; Torbenson M; Astemborski J; Faruki H; Spoler C; Rai R; Mehta S; Kirk GD; Nelson K; Afdhal N; Thomas DL
Hepatology; 2006 Apr; 43(4):788-95. PubMed ID: 16557548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
